Pfizer / BioMtech’s COVID-19 vaccine does not increase the risk of serious cardiovascular problems (heart attack, stroke or pulmonary embolism) in people over 75, according to an official French study released Monday.
The authors concluded that vaccination with Pfizer / BioMtech “after 75 or more years of age does not seem to increase the risk of serious cardiovascular events” after the first or second injection. .
This work was done within the framework of the EP-Fair Scientific Interest Group, which combines the Medicines Agency (ANSM) and Health Insurance (Cnam).
The researchers considered all cases of hospitalization in France for heart attack, stroke and pulmonary embolism between December 2020 and March 2021 for those aged 75 and over, who were not vaccinated and unvaccinated (i.e. approximately 30,000).
They compared the likelihood of these cardiovascular problems at different times: the 14-day period after the first and second doses of the vaccine were considered risk periods and all other control periods.
“Overall, the frequency frequency of hospitalized cases in people 75 years of age and older for myocardial infarction, ischemic stroke, hemorrhagic stroke or pulmonary embolism did not differ significantly between these different periods,” concludes the L study.
EP-Fair researchers now plan to update this data: “Once information becomes available, analyzes will continue to measure these risks, especially in people with a history of cardiovascular events, the young population, and other COVID-19 vaccines”.
In France, the vaccine campaign began in late December 2020 and was initially limited to the elderly (mainly vaccinated with the Pfizer / BioMTech vaccine).
In May, a previous study focusing on the Pfizer / Bioentech vaccine found that the EP-Fair Group reduced the risk of severe forms of COVID-19 by 87% in those older than 75 days after vaccination. The second dose.